Abstract:Activation of mineralocorticoid receptors (MR) by its agonist aldosterone induces several unwanted processes like inflammation, fibrosis, increase of blood pressure and ventricular hypertrophy. Inversely, the blockade of MR is known as a highly efficacious therapy in chronic heart failure and arterial hypertension. Therapy with currently approved MR antagonists is often limited due to side effects. Recently, new highly selective, non-steroidal aldosterone antagonists such as finerenone have been developed. To investigate the effects of finerenone on progressive cardiac hypertrophy the transverse aortic constriction (TAC) model was used. C57BL/6 male mice underwent a TAC-operation and were treated daily by oral gavage with finerenone (fin; 10 mg/kg/d), eplerenone (200 mg/kg/d) or vehicle (veh). The treatment started one week before the TAC-operation, and was continued 4 weeks postoperative. To examine the efficacy of finerenone on myocardial wall thickening echocardiography was performed one week before and 4 weeks after TAC and left ventricular mass (LVM) was calculated. Furthermore, gene expression analysis in heart and kidney were carried out to investigate molecular mechanisms. TAC-operated mice treated with finerenone showed a significant lower LVM relative to body weight compared with vehicle-treated mice (fin: 3.89 mg/g; veh: 4.32 mg/g; p<0.05). Also the percentage increase of LVM four weeks after TAC was significantly lower in finerenone-treated animals than in vehicle-treated mice (fin: +37.16 %, veh: +52.9 %, p<0.05). Furthermore, markers of pathological hypertrophy like atrial natriuretic factor (ANF) and β-myosin heavy chain (β-MyHC) were measured in the left ventricle, and showed a higher expression in vehicle-treated than finerenone-treated animals. Treatment with eplerenone did not significantly reduce cardiac hypertrophy after 4 weeks post TAC. In conclusion, these data show for the first time beneficial effects of the new non-steroidal MR-antagonist finerenone on LVM development in a TAC-model. The distinct actions of finerenone when compared to eplerenone may result from different MR-blocking properties.

Eplerenone inhibits atrial fibrosis in mutant TGF-β1 transgenic mice

Eplerenone Prevents Atrial Fibrosis Via the TGF-β Signaling Pathway

Aliskiren Ameliorates Pressure Overload-Induced Heart Hypertrophy and Fibrosis in Mice

Regulation of Atrial Fibrosis by the Bone.

Eplerenone regulates hypertrophy in heart failure by microRNA-208 a inhibiting on THRAP 1

PS-B03-9: EPLERENONE PREVENTS CARDIAC FIBROSIS BY INHIBITING ANGIOGENESIS IN UNILATERAL URINARY OBSTRUCTION RATS

EphrinB2 Regulates Cardiac Fibrosis Through Modulating the Interaction of Stat3 and TGF-β/Smad3 Signaling

Fibroblast Growth Factor 21 Protects Against Atrial Remodeling Via Reducing Oxidative Stress.

Epoxyeicosatrienoic Acid Prevents Maladaptive Remodeling in Pressure Overload by Targeting Calcineurin/nfat and Smad-7.

Molecular basis of selective atrial fibrosis due to overexpression of transforming growth factor-β1.

Apelin Attenuates TGF-β1-induced Epithelial to Mesenchymal Transition Via Activation of PKC-ε in Human Renal Tubular Epithelial Cells.

MFGE8 Attenuates Ang-II-induced Atrial Fibrosis and Vulnerability to Atrial Fibrillation Through Inhibition of TGF-β1/Smad2/3 Pathway

599 APOCYNIN AND EPLERENONE ATTENUATES OXIDATIVE STRESS AND CARDIAC FIBROSIS IN ANGIOTENSIN II-INDUCED CARDIAC DIASTOLIC DYSFUNCTION

Astaxanthin Protects Against Renal Fibrosis Through Inhibiting Myofibroblast Activation and Promoting CD8+ T Cell Recruitment.

Eplerenone in Combination with ACE Inhibitor Reduces Post-Myocardial Infarction LV Remodeling and Maintains Function

Eplerenone ameliorates lung fibrosis in unilateral ureteral obstruction rats by inhibiting lymphangiogenesis

Angiotensin II increases CTGF expression via MAPKs/TGF-β1/TRAF6 pathway in atrial fibroblasts.

Abstract 007: Effects Of Finerenone - A Novel Non-steroidal Mineralocorticoid Receptor Antagonist In A Model Of Pressure Overload-induced Cardiac Hypertrophy

Epidermal Growth Factor Receptor Signaling Mediates Aldosterone-Induced Profibrotic Responses in Kidney.

Periplaneta Americana Extract May Attenuate Renal Fibrosis through Inhibiting Janus Tyrosine Kinase 2/Signal Transducer and Activator of Transcription 3 Pathway

Liraglutide inhibits AngII-induced cardiac fibroblast proliferation and ECM deposition through regulating miR-21/PTEN/PI3K pathway